Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD

Figures & data

Table 1 Differences between FDC LABA/LAMA and tiotropium via HandiHaler^® for comparative clinical variables

FDC LABA/LAMA versus tiotropium HandiHaler^® 18 μg	n	AUC FEV1, mL	FEV1 trough, mL	Symptom score (TDI)	Quality of life (SGRQ)
Vilanterol 25/umeclidinium 62.5 μg via Ellipta^® at 24 weeks^Citation71		0–6 hours
	203	74 (22, 125)*	90 (39, 141)*	0.1	Not available
	215	96 (50, 142)*	60 (10, 109)*
Indacaterol 110/glycopyrronium 50 μg via		0–4 hours
Breezhaler^® at 26 weeks^Citation39	2,144	120*	80*	0.51*	−2.13
Formoterol/aclidinium via Genuair^®	Data awaited
Olodaterol/tiotropium 5/2.5 and 5/5 μg via Respimat^®	Data awaited
Olodaterol via Respimat^® plus tiotropium via HandiHaler^® versus tiotropium via		0–3 hours
	1,134	117 (37, 88)*	62 (37, 88)	Not recorded	−1.9 (−2.8, −1.0)
HandiHaler^® at 12 weeks^Citation72	1,137	106 (0.078, 0.135)*	40 (14, 65)		combined data from the two studies

Notes: Mean (95% confidence interval);

* P-value <0.05; n, number of participants.

Abbreviations: FDC, fixed-dose combination; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; AUC, area under the curve; FEV₁, forced expiratory volume in 1 second; TDI, transition dyspnea index; SGQR, St George’s Respiratory Questionnaire.

GlaxoSmithKlineFDA Advisory Committee Briefing Document. ANOROTM ELLIPTATM (umeclidinium bromide/vilanterol inhalation powder) for treatment of chronic obstructive pulmonary disease. NDA 203975. Presented to Pulmonary-Allergy Drug Advisory Committee 2013 Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367414.pdfAccessed December 7, 2014

 Google Scholar

BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616

 PubMed Web of Science ®Google Scholar

ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat® and tiotropium Handi-Haler® in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J COPD2014911331144

 Google Scholar